Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oncaspar

Bristol-Myers Squibb (BMS) building

Opdivo plus Yervoy effective first-line in lung cancer

Study shows immuno-oncology agents work well together

Bristol-Myers Squibb (BMS) building

BMS’ myeloma treatment accepted for priority review

If approved elotuzumab will be marketed as Empliciti

AstraZeneca appoints Sean Bohen as chief medical officer

Dr Bohen will join the firm from Genentech

- PMLiVE

AZ and Peregrine join forces on cancer trial

Another oncology deal for the company after a recent spate of deals

- PMLiVE

Jardiance is first diabetes drug to improve CV outcomes

Lilly/Boehringer drug could gain market share boost from new data

Roche Basel Switzerland

Roche’s PD-L1 drug shrinks lung tumours

Drug has already showed success in treating certain bladder cancer patients

Shire Basingstoke

Baxalta spells out opposition to Shire

Firm has rejected unsolicited $30bn bid from the Irish biopharma

- PMLiVE

AZ adds cancer vaccine to immuno-oncology portfolio

Firm's biologics unit adds to string of oncology deals in 2015

- PMLiVE

MedImmune appoints Dr Christopher Rhodes

Will head cardiovascular and metabolic diseaseresearch for the AZ unit

- PMLiVE

AZ signs two more deals in cancer immunotherapy

Anglo-Swedish firm pens partnerships with Heptares and Mirati Therapeutics

National Institute for Health and Care Excellence NICE logo

Another NICE no for AZ’s new ovarian cancer drug

Cost watchdog wants more information for Lynparza

- PMLiVE

Shire makes shock $30bn bid for Baxalta

Irish firm seeking to buy the newly spun-out biotech that used to be part of Baxter

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links